PMID- 18463539
OWN - NLM
STAT- MEDLINE
DCOM- 20081031
LR  - 20210102
IS  - 1524-9557 (Print)
IS  - 1524-9557 (Linking)
VI  - 31
IP  - 5
DP  - 2008 Jun
TI  - Melanoma and lymphoma rejection associated with eosinophil infiltration upon 
      intratumoral injection of dendritic and NK/LAK cells.
PG  - 458-65
LID - 10.1097/CJI.0b013e318174a512 [doi]
AB  - Dendritic cells (DCs) are promising tools for tumor immunotherapy. Their efficacy 
      in the tumor environment increases when tumor cells die as a consequence of 
      chemo/radiotherapy or when local stimuli promoting DC maturation and function are 
      available. Dying tumor cells could represent a source of tumor antigens, which 
      DCs cross-present to tumor-specific T cells. The outcome of cross presentation is 
      in turn determined by the maturation state of DCs. Natural killer 
      (NK)/lymphokine-activated killer (LAK) cells injected into growing tumors could 
      both provide a source of dying cells for cross-presentation and deliver stimuli 
      for DC maturation. Here, we report that NK/LAK cells recognized and killed in 
      vivo major histocompatibility complex class I(low) highly tumorigenic, 
      nonimmunogenic B16F1 melanoma cells when injected into exponentially growing 
      neoplastic lesions. The simultaneous injection of immature DCs was required to 
      heal animals. Similar results were obtained injecting NK/LAK cells and DC into 
      growing Raucher leukaemia virus induced cell line lymphomas. Cured mice failed to 
      reject other implantable tumors, and developed a specific cytotoxic response 
      against the original neoplasm; moreover, they developed a long-lasting memory, 
      and were protected against further challenges with living tumor cells only when 
      both cell populations were introduced. The response associated to the 
      preferential recruitment within tumors of eosinophils. The simultaneous injection 
      in solid tumors of DCs and NK/LAK cells represents an attractive approach for 
      antineoplastic immunotherapeutic strategies.
FAU - Capobianco, Annalisa
AU  - Capobianco A
AD  - Department of Oncology, Cancer Immunotherapy and Gene Therapy Program, Clinical 
      Immunology Unit, H San Raffaele Scientific Institute and Universita Vita-Salute 
      San Raffaele, Milano, Italy.
FAU - Manfredi, Angelo A
AU  - Manfredi AA
FAU - Monno, Antonella
AU  - Monno A
FAU - Rovere-Querini, Patrizia
AU  - Rovere-Querini P
FAU - Rugarli, Claudio
AU  - Rugarli C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Immunother
JT  - Journal of immunotherapy (Hagerstown, Md. : 1997)
JID - 9706083
SB  - IM
MH  - Animals
MH  - Cell Line, Tumor
MH  - Dendritic Cells/*immunology/transplantation
MH  - Eosinophils/*immunology
MH  - *Immunotherapy
MH  - Killer Cells, Natural/*immunology/transplantation
MH  - Lymphoma/*immunology
MH  - Melanoma/*immunology
MH  - Mice
MH  - Neoplasms/*immunology/*therapy
MH  - Phenotype
MH  - Survival Rate
MH  - Time Factors
EDAT- 2008/05/09 09:00
MHDA- 2008/11/01 09:00
CRDT- 2008/05/09 09:00
PHST- 2008/05/09 09:00 [pubmed]
PHST- 2008/11/01 09:00 [medline]
PHST- 2008/05/09 09:00 [entrez]
AID - 00002371-200806000-00004 [pii]
AID - 10.1097/CJI.0b013e318174a512 [doi]
PST - ppublish
SO  - J Immunother. 2008 Jun;31(5):458-65. doi: 10.1097/CJI.0b013e318174a512.